Skip to content
Home/Companies/HealthTech/Affect Therapeutics
Affect Therapeutics

Affect Therapeutics

HealthTech·United States·Active·3yr hold
Entry
2023
Hold
3yr
Status
Active

Who owns Affect Therapeutics?

Affect Therapeutics is currently owned by LifeArc through LifeArc Ventures (1992 vintage), since 2023.

Hand-verified · updated 2026-05-31

LifeArc
Investor
LifeArc
LifeArc Ventures · 1992 · Life Sciences VC

Key facts

HQUnited States
SectorHealthTech
StatusActive
Websitewww.affect.com

More from LifeArc Ventures

Other portfolio companies in the same fund.

Exciva
Active
BiotechGermany· 2026
GlycoEra
Active
BiotechSwitzerland· 2025
Hillstar Bio
Active
BiotechUnited States· 2025
Tribune Therapeutics
Active
BiotechSweden· 2025
Fluid Biomed
Fluid Biomed
Active
MedTechCanada· 2024
Cytospire Therapeutics
Cytospire Therapeutics
Active
BiotechUK· 2023

More PE-backed in HealthTech

Comparable healthtech deals from other GPs.

52North Health
52North Health
Active
Future Planet CapitalUK
Akrivia Health
Akrivia Health
Active
Future Planet CapitalUK
Paladin
Paladin
Active
Ring CapitalFrance
Access Infinity
Active
CBPE CapitalUK· 2026
Auryx
Active
VentoUnited Kingdom· 2026
Axomove
Axomove
Active
INCO VENTURESFrance· 2026
Track Affect Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Affect Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue